efficacy and safety of sarecycline in patients with acute ischemic stroke after reperfusion therapy

Conditions: Ischemic Stroke, Acute

Summary: the aim of this study was to evaluate the efficacy and safety of sarecycline versus placebo in the treatment of microcirculation dysfunction after reperfusion therapy in patients with large vessel occlusion stroke.

this study evaluated the efficacy and safety of 7-day sarecycline versus placebo in patients with large vessel occlusion stroke who received reperfusion therapy within 24 hours of onset. in addition, we will explore the effect of sarecycline versus placebo on indicators of venous thrombotic inflammation at different time points in patients with acute ischemic stroke with large vessel occlusion. this trial was a prospective, randomized, multicenter, double-blind, placebo-controlled parallel trial. patients with acute large vessel occlusion stroke who received reperfusion therapy within 24 hours of onset were randomly assigned according to the ratio of the experimental group: control group =2:1. the trial was divided into three phases: screening/baseline period, treatment period, and follow-up period. the primary research objective is to evaluate the effect of sarecycline in improving neurological deficits at 7 days in patients with acute large vessel occlusion stroke who received reperfusion therapy within 24 hours of onset.

Eligibility criteria:
inclusion criteria: 1. 18≤age≤80 years old; 2. acute large vessel occlusion (lvo) confirmed by imaging (ct+cta+ctp/mri+mra), including the responsible vessel was located in the intracranial internal carotid artery, the t-shaped branch, the m1/m2 segment of the middle cerebral artery, or the a1/a2 segment of the anterior cerebral artery; 3. aspects≥6; 4. 7≤nihss≤25,and ia≤1; 5. scheduled for reperfusion therapy within 24 hours of onset (including intravenous rt-pa or tnk-tpa thrombolysis (within 4.5 hours), mechanical thrombectomy, and bridging therapy); 6. first stroke or complete self-care before the onset of current stroke (mrs 0-1); 7. patients or his/her legal representatives are able to understand and sign the informed consent. exclusion criteria: 1. history of pseudomembranous colitis or antibiotic-related colitis. 2. allergic to tetracycline antibiotics or any component of the investigational drug. 3. known to be resistant to other tetracyclines. 4. history of intracranial hemorrhagic diseases within the previous 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/external hematoma, etc. 5. intracranial tumors, vascular malformations, and other intracranial space-occupying lesions. 6. bilateral or posterior circulation lvo. 7. rare or unknown etiology of lvo, such as dissection and vasculitis. 8. severe hepatic or renal insufficiency and various reasons for receiving dialysis before randomization (severe hepatic insufficiency was defined as alt \>3 times the upper limit of normal value or ast \>3 times the upper limit of normal value; severe renal insufficiency refers to serum creatinine \>3.0 mg/dl (265.2 μmol/l) or glomerular filtration rate\<30 ml/min). 9. bleeding tendency (including but not limited to): platelet count \ 2; received heparin within previous 48 hours, aptt≥35s; hereditary hemorrhagic diseases, such as hemophilia. 10. received any of the following treatments within the previous 3 months: systemic retinoic acid, androgen/antiandrogen therapy (e.g., anabolic steroids, andiolactone). 11. refractory hypertension that is difficult to control with medication (systolic blood pressure \>180 mmhg or diastolic blood pressure \>110 mmhg). 12. history of intracranial or spinal surgery within the previous 3 months; history of therapeutical surgery or major physical trauma within the previous 1 month. 13. have other investigator-evaluated contraindications of reperfusion therapy. 14. women of childbearing age who do not use effective contraception and have no negative pregnancy test records; women during lactation and pregnancy. 15. life expectancy of fewer than 6 months due to advanced stage of any comorbidity. 16. participated in other interventional clinical trials within the previous 3 months. 17. other conditions that are not suitable for participating in this clinical trial, such as inability to understand and/or follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc.

Keywords: ischemic stroke, sarecycline